Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. - Wikidata - awgldk - TriplyDB

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

http://www.wikidata.org/entity/Q36251342

about

KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

P2860

Q34157801-AA9C797F-18A5-4199-97D5-B35DD2387CE3 Q35713515-7E1E6C0B-2B17-45AE-BF4E-2D0332487D5D Q36344419-248B4C68-CFFE-43BC-BC89-4FC61A30F0F2 Q37166407-787AD142-7193-469A-B681-FAE854A327ED Q37513931-1390C27D-980C-4C93-975D-A76D01F64AE2 Q38358391-D5CCE589-23A8-4CF8-AC0F-33F6A68DC2E9 Q38730927-786D8EC9-16D0-4C95-8482-62E2F61FA267 Q38931272-4C803C2E-AE21-4592-B756-C9A25D586B95 Q41662598-2D55A9BB-65F3-4F79-B73B-81C896F38574 Q42314339-52218537-C6A1-4433-81DF-5FBE0A7F20F6 Q44062774-2BF05C2C-D590-49AD-9376-5A9C10F08319 Q45062413-D35D0C30-4FBC-4420-B25F-92877C0BADBB Q48050451-80EBE421-17EA-4033-81F3-B2859863DAA2 Q50201468-8965BCE9-9D1B-44B0-A2A9-D013F65512AA Q53545250-27E8F908-13EA-44F8-928E-B2633D1579CD Q57109641-DDD07823-D6C7-40DF-B4D7-A9D1063F7C91

P2860

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

http://www.wikidata.org/entity/Q36251342

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@ast

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@en

type

label

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@ast

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@en

prefLabel

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@ast

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@en

P1433

Q36251342-9587A55C-09BE-4BEF-84B8-DB130B487585

P1476

Q36251342-5B4417BE-C8F7-492C-9351-673C6A6744C0

P2093

Q36251342-4DFD8FB6-7151-48DC-8552-308EE6FA587D

Q36251342-527E290C-5BF0-4439-974E-B79496BA6A51

Q36251342-90BAC318-6200-4CD2-B4F3-A6CC1609CF6D

Q36251342-9329BCD7-2B2E-4DF6-BBEA-611729736024

Q36251342-A7BC7FFB-EB3E-419D-AD40-FA1216805D21

Q36251342-C95763F3-083E-4D12-A592-FB298471C2EB

Q36251342-E171E83D-96C1-4810-8440-60D63C15A4DC

Q36251342-E842D8F0-1ED5-45D7-9CCF-90A91FFBF7DA

Q36251342-F555DE4A-5E4A-4C98-AE18-6ADE102B26D6

Q36251342-F7093271-F1BD-48B7-8D2A-9DEB53E93E43

P2860

Q36251342-0E896C62-85BA-443D-AF3E-4195982DD5DD

Q36251342-4D94CCF8-63FB-4D3E-B4EE-BD21C39E18B4

Q36251342-4ECCD1E2-99D1-4A87-B814-A915D1BB50CE

Q36251342-542BFA50-1E37-47A5-8DD2-B1822573A757

Q36251342-5E1C663C-781E-4A4E-BC92-82A2A14133F6

Q36251342-6399BE1B-5E27-4D33-B1E0-938EE77DC839

Q36251342-7072F2E1-A158-4F47-A876-79D82B8861B2

Q36251342-74B67F98-89F2-4F33-8E96-4B8D76F0F9B6

Q36251342-7C1FA2B4-E21B-4656-9675-F8A2722A900E

Q36251342-7D043769-143E-42C5-8B63-7C728D03B2FD

P304

Q36251342-D0ACF299-87C8-4E3D-AE84-06014526E982

P31

Q36251342-3119D5CF-2D91-4416-BC29-59AF083CF284

P356

Q36251342-D40AB6F2-65CC-4F72-9642-2C18FF901C2B

P433

Q36251342-3363E658-CB8F-40DB-9745-1DDEADA92CD0

P478

Q36251342-63754035-79C9-45E6-AA9A-BE0F5B887198

P577

Q36251342-F392820C-52D0-4788-AB1A-9848B7D28741

P5875

Q36251342-B811CE75-4F48-4137-9545-CDEFBEAB8EE7

P698

Q36251342-17DF93E8-6116-4591-A661-4778CED44E2B

P932

Q36251342-1E216F45-DF6A-413C-A33B-3552A073C0DB

P356

P1433

Japanese Journal of Clinical Oncology

P1476

Everolimus for advanced pancre ...... tients in the RADIANT-3 trial.

@en

P2093

Akio Kasuga

http://www.w3.org/2001/XMLSchema#string

Chigusa Morizane

http://www.w3.org/2001/XMLSchema#string

Hisato Igarashi

http://www.w3.org/2001/XMLSchema#string

Junji Furuse

http://www.w3.org/2001/XMLSchema#string

Kohei Nakachi

http://www.w3.org/2001/XMLSchema#string

Masafumi Ikeda

http://www.w3.org/2001/XMLSchema#string

Takeshi Tajima

http://www.w3.org/2001/XMLSchema#string

Takuji Okusaka

http://www.w3.org/2001/XMLSchema#string

Tetsuhide Ito

http://www.w3.org/2001/XMLSchema#string

Yoshie Fujita

http://www.w3.org/2001/XMLSchema#string

P2860

TOR signaling in growth and metabolism

Current development of mTOR inhibitors as anticancer agents

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

New treatment options for patients with advanced neuroendocrine tumors.

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Everolimus for advanced pancreatic neuroendocrine tumors.

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.

Population-based study of islet cell carcinoma.

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

P304

903-911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYS123

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230616710

http://www.w3.org/2001/XMLSchema#string

P698

22859827

http://www.w3.org/2001/XMLSchema#string

P932

3448379

http://www.w3.org/2001/XMLSchema#string